Adalimumab-psoriasis and Small Bowel Lesions

Exclusion Criteria

• •Diagnosis of inflammatory bowel's disease
• •Presence of any evidence of gastrointestinal obstruction, strictures and/or fistulas
• •Presence of highly suspected or documented gastroparesis
• •Known presence of gastrointestinal motility disorders
• •Known presence of delayed gastric emptying
• •Prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator
• •Presence of pacemaker, defibrillator or other electromedical device
• •Expected to undergo a MRI examination within 7 days after ingestion of the capsule
• •Swallowing disorder
• •Presence of other skin diseases or skin infections that may interfere with evaluation of psoriasis or with patient's safety at Day 0
• •History of an allergic reaction or significant sensitivity to constituents of study drug, including latex
• •Use of any biological therapy for the treatment of psoriasis less than 90 days before Day 0
• •Use of any other non-biological systemic therapy for the treatment of psoriasis within 28 days before Day 0
• •Is planning to intentionally increase exposure to ultraviolet light at any time during the study period
• •Is taking or requires systemic (i.e., oral or injectable) corticosteroids within 28 days of Day 0 or during the study
• •Used any topical treatments for psoriasis or phototherapy within two weeks prior to Day 0
• •Received Anakinra/Kineret within the last 2 weeks prior to Day 0
• •Used any investigational non-biological agent within 30 days prior to Day 0, or within 5 half lives of the investigational agent prior to day 0
• •Used NSAIDs for 28 days before Day 0
• •Has a poorly controlled medical condition in the opinion of the investigator, would put the patient at risk if participating in the study
• •Multiple sclerosis or presents with or has a history of neurologic symptoms suggestive of CNS demyelinating disease
• •Current signs or symptoms of or a history of systemic lupus erythematosus or lupus like syndrome
• •History of cancer or lymphoproliferative disease other than a successfully treated non metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix
• •History of listeriosis, treated or untreated TB, persistent chronic infections, or recent active infections requiring hospitalization or treatment with intravenous anti-infectives within 30 days or oral anti-infectives within 14 days prior to Day 0
• •Received any live attenuated vaccine 28 days or less before Day 0 or plans to receive one during the study
• •Hepatitis B or hepatitis C
• •Clinically significant abnormal results for hemoglobin, white blood cell count, platelet count, ALT, AST, total bilirubin or creatinine
• •Current use or plan to use anti-retroviral therapy at any time during the study
• •Known immune deficiency or is immunocompromised
• •Current pregnancy or lactation or considering becoming pregnant during the study or for 150 days after the last dose of study medication
• •History of clinically significant drug or alcohol abuse in the last year
• •Is considered by the investigator, for any reason, to be an unsuitable candidate for the study